02-11-2015 | BodyCap | New Technologies
BodyCap, a company specializing in miniaturized wireless monitoring devices, has announced that it has tested its e-Celsius Performance connected pill for temperature monitoring on ten FC Nantes soccer players during two French League 1 games. Using e-Celsius Performance, the club was able to measure the effectiveness of recovery techniques such as ice treatment for players. The e-Celsius Performance is an ingestible pill that continuously monitors the user’s internal temperature, helping to minimize the risks of hypothermia and hyperthermia for elite athletes. It can also help to optimize sporting performance. Once the pill is ingested, the sportsperson has complete freedom of movement, as there is no requirement to wear a monitor. Every 30 seconds, the pill wirelessly transmits the athlete’s gastro-intestinal temperature measurements to a monitor called e-Viewer Performance®. The pill stores measurements for up to 16 hours when away from the monitor. This data is then wirelessly transmitted once the pill is back within the 3-meter range. Staff at FC Nantes used e-Celsius Performance during training and in two French league matches, against Rennes on September 13 and Paris Saint-Germain on September 26. The aim was to analyze the players’ ability to regulate their temperature during warm-up and play and then to track the return to baseline values during recovery. With better knowledge of each player's ability to regulate their core temperature, management of elite sporting performance can be improved. The pill is swallowed a few hours before the start of the match, allowing temperature to be monitored throughout the game while player’s mobility is maintained. The e-Celsius Performance has proven particularly useful in monitoring players during the ice treatment phase of their post-match recovery. This innovative method uses cold temperatures to help the athlete to recover more quickly from their physical exertions and to relieve associated aches and pains. Spending five minutes in a bath at 8C is a key component of recovery for athletes, as it has a positive impact on their physical condition and their sporting performance. “FC Nantes uses advanced techniques to improve player performance. The club is already making use of ice treatment and is keen to measure its impact,” said Philippe Daguillon, the team’s physio and the founder of ice bath specialist Cryobain. “The data obtained from the BodyCap pill will help to introduce individual recovery programs for each player, based on their capacity for recovery, their position on the field and weather conditions. There is real value in developing and expanding on this initial analysis.” The player’s temperature data was retrieved the day after the games. The data helped to create a detailed analysis of each player’s responses and objectively measure the impact of the recovery techniques used by the club, including the post-match sleep. With regular use, the data on individual players should help in fine-tuning and tailoring their training and development programs. The aim is to significantly improve player performance on the pitch and to study their physiological data. Sébastien Moussay, co-founder, BodyCap, added: “We are delighted to be working with FC Nantes. This arrangement confirms the value of our product in elite sport. The positive feedback from the players and staff at the club who tested our pill during the warm-up, match and ice treatment phases is key to the adoption of the product. For us, this is a real acknowledgment of the reliability and added value of our pill. Simple to use and non-invasive, it is one of the best devices currently on the market.” A fast-growing market - The market for elite sport is increasingly turning to connected technologies for use in optimizing sporting safety and performance. The medical care of athletes uses leading-edge technology resources to study sports physiology. Professional sports such as cycling, rugby and soccer lead the way, due to the nature of these sports and the financial stakes. In Europe, there are at least 100 soccer clubs that could have an interest in this technology. “The next big step for our company is the routine use of our pill in elite sports such as cycling, rugby or long-distance running,” continued Moussay. “We are currently working with partners in these sectors and are receiving a large number of inquiries. We also plan to export to the US, where the market for elite sports uses different models from European sport.” BodyCap will be attending the CES trade show, which takes place in Las Vegas from January 6 to 9, 2016, with a view to entering the US market.
